Safety study of belumosudil for chronic graft-versus-host disease
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests an oral medication called belumosudil for people who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It aims to see how safe the drug is. You may qualify if you have already tried at least two other treatments and are currently on a stable steroid dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years old or older.
- You must have had a stem cell transplant from a donor (allogeneic).
- You must have already tried at least 2 previous treatments for chronic graft-versus-host disease (cGVHD).
- You must be on a stable dose of steroids (like prednisone) for the 2 weeks before starting the study.
- Your recent blood counts (white blood cells and platelets) must be above certain minimums, and your liver and kidney function must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called belumosudil to see if it can help people with chronic graft-versus-host disease (a common complication after a stem cell transplant where donor cells attack your body). It is for patients who have symptoms but are not yet on strong immune-suppressing drugs.
This study tests a new medicine called belumosudil for people who have chronic graft-versus-host disease (cGVHD) that has not improved with at least two earlier treatments. It compares belumosudil to other available treatments to see which works better and is safer.
This study tests a new medicine called belumosudil for children with chronic graft-versus-host disease (GVHD) that hasn't improved with at least 2 other treatments. The goal is to see if it can help control the disease and improve symptoms.
This trial tests a combination of two drugs, belumosudil and rituximab, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication that can occur after a stem cell transplant. The goal is to see if this combination can control symptoms and reduce the need for steroids.
This trial tests whether crushing belumosudil tablets changes how the drug works in people with chronic graft-versus-host-disease (GVHD), a complication after a stem cell transplant. It helps doctors know if taking crushed pills is as effective as whole tablets.
This study compares how the body absorbs a drug called belumosudil when given as a liquid versus a tablet. It aims to see if the two forms are similar, which could help decide the best way to give the drug in the future.
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.